Terms: = Head and neck cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Clinical Outcome
4 results:
1. erbb3, a possible prognostic factor of head and neck squamous cell carcinoma.
Kim H; Choi JY; Rah YC; Ahn JC; Kim H; Jeong WJ; Ahn SH
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Apr; 129(4):377-387. PubMed ID: 32081558
[TBL] [Abstract] [Full Text] [Related]
2. Antitumor effect of insulin-like growth factor-1 receptor inhibition in head and neck squamous cell carcinoma.
Lehman CE; Khalil AA; Axelrod MJ; Dougherty MI; Schoeff SS; Taniguchi LE; Mendez RE; David AP; McGarey PO; Hubbard MA; Donaldson L; Frierson HF; Stelow EB; Bekiranov S; Wulfkuhle JD; Petricoin EF; Gioeli DG; Jameson MJ
Laryngoscope; 2020 Jun; 130(6):1470-1478. PubMed ID: 31433065
[TBL] [Abstract] [Full Text] [Related]
3. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of erbb3 overexpression in oral squamous cell carcinoma.
Shintani S; Funayama T; Yoshihama Y; Alcalde RE; Matsumura T
Cancer Lett; 1995 Aug; 95(1-2):79-83. PubMed ID: 7656248
[TBL] [Abstract] [Full Text] [Related]
